# Phase Ib of L-NMMA and Pembrolizumab

> **NCT03236935** · PHASE1 · COMPLETED · sponsor: **The Methodist Hospital Research Institute** · enrollment: 12 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Malignant Melanoma
- Head and Neck Squamous Cell Carcinoma
- Classical Hodgkin Lymphoma
- Urothelial Carcinoma Bladder
- DNA Repair-Deficiency Disorders

## Interventions

- **DRUG:** L-NMMA
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03236935
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-27
- **Primary completion:** 2021-10-31
- **Final completion:** 2022-04-22
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03236935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03236935, "Phase Ib of L-NMMA and Pembrolizumab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03236935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*